← Back to Search

Light Therapy

Acne Mask for Acne Vulgaris

N/A
Waitlist Available
Led By Michael H Gold, M.D.
Research Sponsored by Johnson & Johnson Consumer Inc. (J&JCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 28
Awards & highlights
No Placebo-Only Group

Summary

The study will look to evaluate the tolerance of a light therapy-based acne mask device in participants who report having sensitive skin. All participants will receive a cleanser, a light therapy mask, and an extra activator for the light therapy mask.

Eligible Conditions
  • Acne Vulgaris
  • Acne

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 28 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cutaneous Tolerance Scores: Tightness/Dry Feeling
Secondary study objectives
Cutaneous Tolerance Scores: Burning/Stinging
Cutaneous Tolerance Scores: Dryness/Scaling
Cutaneous Tolerance Scores: Edema
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Acne MaskExperimental Treatment1 Intervention
The light therapy acne mask is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acne Mask
2017
N/A
~150

Find a Location

Who is running the clinical trial?

Johnson & Johnson Consumer Inc. (J&JCI)Lead Sponsor
54 Previous Clinical Trials
5,536 Total Patients Enrolled
3 Trials studying Acne Vulgaris
252 Patients Enrolled for Acne Vulgaris
Michael H Gold, M.D.Principal InvestigatorTennessee Clinical Research Center
~5 spots leftby Dec 2025